Affordable Access

deepdyve-link
Publisher Website

A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery

Authors
  • Weil, Gary J1
  • Jacobson, Julie A2
  • King, Jonathan D3
  • 1 Department of Medicine, Washington University School of Medicine, USA , (United States)
  • 2 Bridges to Development, USA , (United States)
  • 3 Department of Control of Neglected Tropical Diseases, World Health Organization, Switzerland , (Switzerland)
Type
Published Article
Journal
International Health
Publisher
Oxford University Press
Publication Date
Dec 22, 2020
Volume
13
Issue
Suppl 1
Identifiers
DOI: 10.1093/inthealth/ihaa046
PMID: 33349879
PMCID: PMC7753162
Source
PubMed Central
Keywords
License
Unknown

Abstract

The Global Programme to Eliminate Lymphatic Filariasis (LF) is using mass drug administration (MDA) of antifilarial medications to treat filarial infections, prevent disease and interrupt transmission. Almost 500 million people receive these medications each year. Clinical trials have recently shown that a single dose of a triple-drug combination comprised of ivermectin, diethylcarbamazine and albendazole (IDA) is dramatically superior to widely used two-drug combinations for clearing larval filarial parasites from the blood of infected persons. A large multicenter community study showed that IDA was well-tolerated when it was provided as MDA. IDA was rapidly advanced from clinical trial to policy and implementation; it has the potential to accelerate LF elimination in many endemic countries.

Report this publication

Statistics

Seen <100 times